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Objective: To compare the safety and efficacy of dabigatran to warfarin for the treatment of
deep vein thrombosis and pulmonary embolism.
Background: Venous thromboembolism (VTE) is a disease comprised of two conditions: deep
vein thrombosis and pulmonary embolism. VTE is a major cause of morbidity and mortality
worldwide with an annual incidence estimated at 1–3 cases per 1,000 individuals. This incidence
increases with age from 0.1 per 1,000 in adolescence to eight per 1,000 in those 80 years of
age and older. As the proportion of patients 65 years of age and older expands, the number
of patients presenting with VTE will also increase. Anticoagulation remains the cornerstone
of VTE treatment. Traditionally, vitamin K antagonists have been used to minimize the risk of
thrombus extension and for secondary prevention. Unpredictable pharmacokinetics and pharmacodynamics, routine monitoring, drug–food and drug–drug interactions, and potentially severe
adverse events have all been cited as barriers to optimal care. Dabigatran has been proposed as
a suitable alternative to warfarin therapy in the treatment of VTE. Therefore, a critical appraisal
of dabigatran’s safety and efficacy is necessary to determine its role in therapy.
Conclusion: Dabigatran remains an alternative to warfarin therapy for the treatment of VTE.
However, dabigatran also has distinct disadvantages that warrant consideration. Clinicians
must ensure that drug characteristics align with patient characteristics to optimize patient
outcomes.
Keywords: venous thromboembolism, pulmonary embolisms, venous thrombosis, anticoagulants, warfarin sodium, dabigatran etexilate mesylate

Introduction

Correspondence: Kelechi C Ogbonna
Department of Pharmacotherapy
and Outcomes Science, Virginia
Commonwealth University School
of Pharmacy, 410 North 12th Street,
PO Box 980533, Richmond, VA,
USA 23298-0533
Tel +1 804 628 5071
Fax +1 804 828 0343
Email kcunegbuogbo@vcu.edu

Venous thromboembolism (VTE) is a disease comprised of two conditions: deep
vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot most
often found affecting areas of stasis within the veins of the lower leg or thigh,
whereas PE occurs when part of a clot detaches, travels, and lodges in the pulmonary arteries, causing a potentially fatal condition.1 VTE is a major cause of
morbidity and mortality worldwide with an annual incidence estimated at 1–3 cases
per 1,000 individuals.2,3 This incidence increases with age from 0.1 per 1,000 in
adolescence to eight per 1,000 in those 80 years of age and older.2–4 In Europe and
the United States, death attributed to VTE is thought to exceed 400,000 annually.5,6
As the proportion of patients 65 years of age and older expands, the number of
patients presenting with VTE will also increase.4 Therefore, timely identification
and aggressive treatment is essential to reducing morbidity and mortality associated with this disease.
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Risk factors, clinical presentation, and
diagnosis
Several risk factors for developing VTE have been extensively
studied and identified (Table 1).7–11 Patients with a prior history
of VTE and/or those who have cancer are at particularly high
risk of developing DVT and progressing to PE.12 Likewise,
orthopedic procedures, trauma, and hypercoagulability disorders have also been linked to an increased incidence of VTE.4,12
Despite extensive knowledge pertaining to the precipitating
factors for VTE, early detection remains challenging.
VTE symptoms are generally nonspecific and often
require objective tests for proper diagnosis.13 Discomfort
in the calf muscle on passive dorsiflexion of the foot, also
known as Homans’ sign, was once considered the key clinical
indicator of DVT. This sign has since fallen out of favor as it
is present in less than one-third of patients with confirmed
DVT, it is found in more than 50% of patients without DVT,
and it may pose a risk for embolization.14 Instead, clinicians
should review complaints of leg pain, swelling, edema, or
tenderness on palpation.15 Other symptoms of DVT may
include redness, unexplained fever, increased visibility of
skin veins, or bluish discoloration.
Progression to PE occurs in approximately 50% of
untreated proximal DVT cases.12 Patients with PE typically
present with sudden-onset chest pain, shortness of breath,
Table 1 VTE risk factors
Strong risk factors
Fracture (hip or leg)
Hip or knee replacement
Major general surgery
Major trauma
Spinal cord injury
History of VTE
Moderate risk factors
Central venous lines
Chemotherapy
Congestive heart or respiratory failure
Hormone replacement therapy
Cancer
Oral contraceptives
Paralytic stroke
Pregnancy, postpartum
Thrombophilia
Weak risk factors
Bed rest .3 days
 Increasing age (.60 years)
Obesity (BMI over 30 kg/m2)
Pregnancy, antepartum
 Varicose veins
Notes: With kind permission from Springer Science+Business Media: Frederick
AA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;
107(23 Suppl I):9–16.34
Abbreviations: VTE, venous thromboembolism; BMI, body mass index.
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tachypnea, and tachycardia. PE is a life-threatening condition
and may result in cardiopulmonary collapse.16 For these
reasons, quick identification of VTE is crucial.
Radiographic contrast studies remain the gold standard
for the diagnosis of DVT (venography) and PE (pulmonary
angiography). However, their utility in clinical practice is limited. The invasive nature of the studies and need for contrast
agents, particularly in critically-ill patients, may pose more
risk than benefit.13 Radiographic contrast studies are also significantly more expensive than the available alternatives. Less
invasive tests, such as compression ultrasound, ventilation–
perfusion scan, and computed tomography scans are more
commonly used in clinical practice for the initial evaluation
of suspected VTE.17

Treatment strategies
Anticoagulation remains the cornerstone of VTE treatment.
Once the diagnosis of VTE has been confirmed, anticoagulant
therapy should begin. Treatment can be divided into two
phases: 1) rapid initiation to minimize the risk of thrombus
extension; and 2) maintenance for secondary prevention.18
Phase 1, or the acute stage of VTE treatment, is generally
7 days and requires rapidly acting anticoagulants such as
unfractionated heparin, low-molecular-weight heparin
(LMWH), and fondaparinux.15 The maintenance phase features continued anticoagulation, traditionally with a vitamin
K antagonist (VKA), intended to reduce the risk of long-term
sequelae (ie, post-thrombotic syndrome).15 This second phase
of therapy allows the body to slowly dissolve the clot via
endogenous thrombolytic processes.
The optimal duration of therapy varies. Patients may continue on anticoagulant therapy beyond 3 months, depending
on the clot’s etiology and site. Patient risk factors pertaining
to clotting as well as bleeding will also need to be assessed
prior to treatment.15 In life- or limb-threatening situations,
anticoagulation may be insufficient. Elimination of the
obstructing thrombus may be necessary, and the use of
thrombolysis or thrombectomy can be considered.15
As beneficial as anticoagulants have proven to be in
the treatment of VTE, they also come with substantial risk.
The anticipation surrounding the development of the targetspecific oral anticoagulants (TSOACs), including dabigatran,
rivaroxaban, apixaban, and edoxaban, has stemmed from
the challenges that typically accompany VKA therapy.
Unpredictable pharmacokinetics and pharmacodynamics,
routine monitoring, drug–food and drug–drug interactions,
and potentially severe adverse events have all been cited
as barriers to optimal care.19 Dabigatran has been proposed as
a suitable alternative to warfarin therapy in the treatment of
Journal of Blood Medicine 2015:6
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VTE. A critical appraisal of dabigatran’s safety and efficacy
is necessary to determine its role in therapy.

Dabigatran characteristics
Dabigatran was first approved by the European Commission
and the US Food and Drug Administration (FDA) to reduce
the risk of stroke and systemic embolism in patients with
nonvalvular atrial fibrillation in 2008 and 2010, respectively.
Dabigatran has since been approved for the treatment and
prevention of recurrence of DVT and PE in the USA and
Europe, with availability in over 100 countries. Dabigatran
is a specific, competitive, and reversible direct thrombin
inhibitor. Thrombin enables the conversion of fibrinogen into
fibrin during the coagulation cascade. Thus, dabigatran’s inhibition of thrombin prevents clot formation. Unlike warfarin,
dabigatran only elicits an effect on one factor within the
coagulation cascade, possibly allowing for a more predictable
pharmacokinetic profile.20

Pharmacokinetic and pharmacodynamic
properties
Another differentiating characteristic of dabigatran is its
formulation. Formulated as a prodrug, dabigatran etexilate
requires hydrolysis for conversion to the active moiety.
Dabigatran etexilate is also dependent on an acidic environment for consistent and predictable absorption. For this reason, the drug is applied to a tartaric acid core, which is then
encapsulated (Figure 1). The tartaric acid core provides
a stable acidic environment, making the formulation less
dependent on gastrointestinal acidity.

Dabigatran etexilate (DE)
Tartaric acid core

PGP

DE

DE

Esterases

Enterocyte

D

Liver

D DG
Kidney

Lumen

Key:
•
•
•
•

DE = dabigatran etexilate
D = dabigatran
DG = dabigatran glucuronides
PGP = P-glycoprotien transporter

Figure 1 D characteristics (absorption, distribution, metabolism, excretion).
Note: Reproduced from Risk versus benefit of non-vitamin K dependent
anticoagulants compared to warfarin for the management of atrial fibrillation in the
elderly. Circulation. 2013;30(7):513–525, Ogbonna KC, Jeffery SM.28
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Special considerations
The lack of routine monitoring with dabigatran is a distinct
advantage over VKAs. However, there are special considerations with dabigatran that are worth noting. Dabigatran has a
relatively short half-life (∼12 hours) requiring twice-daily dosing.22 Therefore, careful attention to adherence with dabigatran
is required. Without routine monitoring to assist in identifying
nonadherent patients, clinicians will need to educate and inform
patients regarding the increased risk of stroke associated with
poor adherence. Dabigatran has a quick onset of action as it
achieves maximum serum concentration (Cmax) in 1 hour.22
While this can be advantageous, it also means that there is a
very short duration of action. This may expose a nonadherent
patient to unnecessary risk if not taken properly.
Urgent reversal options for dabigatran include hemodialysis, charcoal, antifibrinolytics, and coagulation factor replacement.23 While each of these options has their own respective
advantages and disadvantages, the clinical utility of each
remains in question. For example, although hemodialysis can
decrease dabigatran levels by 60%–70%, it requires central
venous access.23 Fortunately, a reversal agent for dabigatran
is in development. Idarucizumab is a humanized monoclonal
antibody fragment that has a 350 times higher affinity for

Circulation

DE

DE

Dabigatran has less drug–drug interactions than warfarin;
however, drug concentrations can be influenced by the
activity of P-glycoprotein transporters. These efflux pumps
prevent the absorption of dabigatran etexilate and propel
the drug back into the intestinal lumen. Drugs that induce
or inhibit P-glycoprotein transporters may affect dabigatran
plasma concentrations (Table 2). Finally, dabigatran is primarily excreted via the kidney (∼80%). As a result, dabigatran
exposure is increased in patients with renal impairment,
which correlates with the severity of the disease.20,21

Table 2 Inhibitors and inducers of P-glycoprotein
Inhibitors
Amiodarone
Ketoconazole/itraconazole
Clarithromycin/erythromycin
 Verapamil
Diltiazem
Quinidine
Protease inhibitors
Sirolimus/tacrolimus
Inducers
Rifampicin
St John’s Wort
Carbamazepine
Phenytoin
Note: Data from Fenner et al.35
submit your manuscript | www.dovepress.com
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dabigatran than thrombin. Thus far, no immunogenic reactions have been observed.23 In early 2015, using interim data
from an ongoing Phase III study,24 Boehringer Ingelheim
(Ingelheim, Germany) submitted applications for approval
to the European Medicines Agency, US FDA, and Health
Canada.25 The US FDA has designated idarucizumab as a
“Breakthrough Therapy”, which will allow for an accelerated
approval pathway.4
Dabigatran offers a promising alternative to traditional
oral anticoagulant therapy based on its pharmacokinetic and
pharmacodynamic characteristics. It is, however, important
to evaluate clinical trials investigating the safety and efficacy
of dabigatran in the prevention and treatment of VTE.

VTE trial data
Phase I: acute treatment of VTE

RE-COVER (number [n] =2,564) and RE-COVER II
(n=2,589) evaluated dabigatran for the acute treatment of
VTE.26,27 Both trials used a randomized, double-blind, doubledummy design to compare a fixed dose of dabigatran (150 mg
twice daily) with dose-adjusted warfarin (international normalized ratio [INR]: 2.0–3.0) for a 6-month period (Table 3).
Initial parenteral anticoagulation was administered for at least
5 days in each study. The primary outcome for both trials was
symptomatic and objectively verified recurrent VTE or related
death (ie, fatal PE). Dabigatran was found to be noninferior
in the reduction of recurrent VTE when compared to warfarin

in RE-COVER (2.4% vs 2.1%, respectively; hazard ratio
[HR] =1.10; 95% confidence interval [CI]: 0.65–1.84) and
RE-COVER II (2.3% vs 2.2%, respectively; HR =1.08; 95%
CI: 0.64–1.80).26,27 Additionally, rates of bleeding were similar
between dabigatran and warfarin in each trial (RE-COVER
[1.6% vs 1.9%, respectively; HR =0.82; 95% CI: 0.45–1.48]
and RE-COVER II [1.2% vs 1.7%, respectively; HR =0.69;
95% CI: 0.36–1.32]).26,27 While all other adverse effects were
similar between the groups, patients receiving dabigatran in
the RE-COVER study were more likely to experience dyspepsia compared with patients receiving warfarin (2.9% vs
0.6%, respectively; P,0.001), likely due to its formulation
with the tartaric acid core.26,28
RE-COVER II was initiated after the completion of the
original RE-COVER study due to low rates of recurrent
VTE.27 The ability to combine the data from both studies
allows for robust interpretation and confirmation of the
original results of RE-COVER. The additional study provided
an expanded pool of subjects that was more in line with the
general VTE population with the number of patients with
DVT, PE, and both DVT and PE, representing approximately
69%, 23%, and 9%, respectively, of the trial population.26,27
Pooled analysis of the 5,107 patients from RE-COVER and
RE-COVER II maintained noninferiority for the primary
efficacy outcome (2.4% vs 2.2%, respectively; HR =1.09;
95% CI: 0.76–1.57) and similar rates of major bleeding (1.4%
vs 2.0%; HR =0.73; 95% CI: 0.48–1.11).

Table 3 Clinical trials with dabigatran in the treatment of VTE
Trial

RE-COVER

RE-COVER II

RE-MEDY

RE-SONATE

Characteristics
Design

Double-blind; noninferiority

Double-blind; noninferiority

Double-blind;
noninferiority
2,856
DAB 150 mg BID

Double-blind;
superiority
1,343
DAB 150 mg
BID
Placebo

n (patients)
 Intervention

2,539
Heparin $5 days followed by
DAB 150 mg BID
Control
Heparin $5 days and doseadjusted warfarin (INR: 2.0–3.0)
 Intended duration
6 months
TTR (%)
60
Results – efficacy: VTE or VTE-related/unexpected death
Hazard ratio
1.10
(95% CI)
(0.65–1.84)
P-value for
Noninferiority ,0.001
Results – safety: clinically relevant or major bleeding
Hazard ratio
0.63
(95% CI)
(0.47–0.84)
P-value
0.002

2,568
Heparin $5 days followed by
DAB 150 mg BID
Heparin $5 days and doseadjusted warfarin (INR: 2.0–3.0)
6 months
57

Dose-adjusted warfarin
(INR: 2.0–3.0)
18 months
64

6 months
NA

1.08
(0.64–1.80)
Noninferiority ,0.001

1.44
(0.78–2.64)
Noninferiority 0.014

0.08
(0.02–0.25)
Superiority
,0.001

0.62
(0.45–0.84)
0.001

0.54
(0.41–0.71)
,0.001

2.92
(1.52–5.60)
0.0013

Note: Data from Schulman et al,26 Schulman et al,27 and Schulman et al.29
Abbreviations: VTE, venous thromboembolism; n, number; DAB, dabigatran; BID, twice daily; INR, international normalized ratio; TTR, time in therapeutic range; NA, not
applicable; CI, confidence interval.
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Phase II: extended treatment of VTE
Extended treatment of VTE with dabigatran was studied in two
separate trials, RE-MEDY and RE-SONATE.29 RE-MEDY
compared the noninferiority of dabigatran 150 mg twice daily
vs dose-adjusted warfarin (INR: 2.0–3.0), while RE-SONATE
compared the superiority of the same dose of dabigatran vs
placebo. Patients in both trials had objectively confirmed
symptomatic proximal DVT or PE and completed at least 3
months of treatment with warfarin or dabigatran.
In the RE-MEDY trial, dabigatran demonstrated noninferiority compared with warfarin for the primary efficacy endpoint of recurrent, objectively confirmed, symptomatic VTE or
VTE-related death (HR =1.44; 95% CI: 0.78–2.64) (Table 3).29
Major bleeding was considerably lower with dabigatran when
compared with warfarin; however, it did not achieve statistical
significance (P=0.06). There was, however, an increased risk
of acute coronary syndrome (ACS) in patients randomized
to dabigatran (0.9% vs 0.2%; P=0.02), furthering concerns
observed in previous trials.29,30
In the RE-SONATE trial (dabigatran vs placebo) dabigatran
demonstrated a significant reduction (92%) in the primary
endpoint of objectively confirmed symptomatic VTE or unexpected death, representing superiority over placebo (HR =0.08;
95% CI: 0.02–0.25).29 While major bleeding alone was not
significantly increased with dabigatran, the composite of major
or clinically relevant nonmajor bleeding was significantly
increased with dabigatran (HR =2.92; 95% CI: 1.52–5.60).
The risk of “any bleeding” was also significantly increased
with dabigatran use (HR =1.82; 95% CI: 1.23–2.68). Despite
the increased risk of ACS observed in the RE-MEDY trial, there
was no difference between the two groups in RE-SONATE. This
may again speak to the protective effects of warfarin and less
so to the harmful effects of dabigatran, as a similar finding was
observed in dabigatran’s atrial fibrillation studies.27–30

Special populations
Older adults
The incidence of VTE and recurrent VTE increases with
age and older adults are at a higher risk for death from PE.3
Furthermore, the risk of bleeding associated with treatment is
higher in this population as well.3 The advent of TSOACs is
promising in this group of individuals because of the increased
potential for drug–drug interactions with warfarin and the
need for frequent monitoring. However, dabigatran is highly
dependent on renal elimination, which can be problematic
considering renal impairment is common in the elderly due to
age-related changes in renal function and the high prevalence
of chronic kidney disease. This may lead to a greater risk

Journal of Blood Medicine 2015:6
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of bleeding in the elderly, particularly those with poor renal
function. The use of dabigatran in the elderly is not well established, as this population has been underrepresented in clinical
trials. This is especially true for those $75 years of age.
The mean age for patients in RE-COVER and RECOVER II was ,60 years, and only 10.4% of the population
was $75 years of age.26,27 Despite the small sample of elderly
patients, subgroup analyses found no difference between the
efficacy of dabigatran and warfarin. However, a meta-analysis
found dabigatran to be associated with a greater risk (relative
risk [RR] =0.91 95% confidence interval [CI] [0.36–2.26])
of major bleeding in subjects $75 years of age compared to
apixaban and rivaroxaban (RR =0.23 95% CI [0.08–0.69];
RR =0.27 [0.13–0.59, respectively].3 Although the overall
trial results with dabigatran showed a reduced risk of major
bleeding with dabigatran when compared to warfarin, there
appears to be a greater risk of major bleeding in those $75
years of age. Additional studies in this population are warranted to determine the role of dabigatran in the elderly.

Renal impairment
While dabigatran offer several advantages over warfarin,
the safety and efficacy of dabigatran in patients with renal
impairment is a concern. Dabigatran significantly depends
on renal elimination (80% of total clearance), much more so
than the other TSOACs.22 Pharmacokinetic data shows a 3.2fold increase in the area under the curve (AUC) for patients
with moderate renal impairment (creatinine clearance [CrCl]:
30–50 mL/minute), while a 6.3-fold increase in the AUC
was found using pharmacokinetic modeling.22 Moderate
renal impairment increases the Cmax and half-life minimally,
so no additional dose adjustment is recommended for those
individuals; however, severe renal impairment has a profound
effect on Cmax and half-life.22 Of note, this was the basis for the
75 mg twice-daily dose for stroke prophylaxis in patients with
atrial fibrillation and a CrCl of 15–30 mL/minute, but this
dose has not been evaluated in clinical trials. Currently, there
are no dosing recommendations for dabigatran when used for
VTE prevention or treatment in patients with CrCl ,30 mL/
minute.22 Due to the paucity of data in this subset of patients,
the manufacturer recommends avoiding dabigatran in patients
with CrCl ,30 mL/minute.22
Although individuals with severe renal impairment
(CrCl ,30 mL/minute) have been excluded from clinical
trials with all of the TSOACs, we can draw some fundamental conclusions from enrolled subjects with mild–moderate
renal impairment. A subgroup analysis of subjects with reduced
renal function (CrCl #50 mL/minute) found a lower risk of
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VTE recurrence with dabigatran compared to warfarin, but this
was not statistically significant (RR =0.11; 95% CI: 0.01–1.88).3
Of note, apixaban and rivaroxaban appear to be associated with
an increased risk in recurrence in patients with reduced renal
function.3 Despite the small sample, the risk of major bleeding
was 7.2 times higher in subjects with a CrCl #50 mL/minute
compared to subjects with a CrCl .50 mL/minute.3 Note the
risk of major bleeding with warfarin was only 2.9 times higher
in those with a CrCl #50 mL/minute.3

Cancer
Cancer is an independent risk factor for VTE and 20% of all
VTEs occur in individuals with cancer.31 The pathophysiology is multifactorial, often involving pre-existing risk factors
(eg, obesity, age) and cancer-specific risk factors (eg, the
type of cancer, chemotherapy). The recommended long-term
treatment for VTE in cancer patients is LMWH because of its
superior efficacy over warfarin.32 However, not all patients
are candidates for LMWH, especially if they have severe
renal impairment or if it is the patient’s preference not to
perform daily injections. While warfarin is a reasonable
alternative, it has many disadvantages. Thus, the TSOACs are
appealing since these agents are administered orally instead
of via subcutaneous injection.
None of the TSOACs, including dabigatran, have been
studied exclusively in patients with active cancer. Those with
cancer were, however, allowed to enroll in RE-COVER and
RE-COVER II, but only 8% of the population from each trial
had cancer.26,27 Furthermore, the eligibility criteria for patients
with cancer were relatively broad and included patients with
recurrent/metastatic cancer, a cancer diagnosis, or any treatment for cancer, in the 5 years preceding study enrollment.
RE-MEDY and RE-SONATE also had similar numbers of
patients with active cancer at baseline.29 Although there were
no differences between dabigatran and warfarin in the subgroups of cancer patients for each of these trials, no concrete
conclusions can be made due to the small number of patients.
Additionally, warfarin is not the preferred option in patients
with cancer, so it is unknown how dabigatran would compare
with LMWH.32 Current guidelines do not recommend any of
the TSOACs for either the prevention or treatment of VTE
in patients with cancer.32 Future studies are warranted and
should compare the efficacy and safety of dabigatran with
LMWH since it is now the standard of care.

Role in therapy
Dabigatran has similar efficacy when compared to warfarin for the treatment of VTE. Although dabigatran offers
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convenience and fewer drug–drug interactions when
compared to warfarin, these attributes are offset by adherence concerns and the lack of a reversal agent. Utilization
in special populations must also be carefully considered,
as dabigatran’s use in renal impairment, cancer, and for
patients .65 years of age requires further investigation.
Dabigatran’s bleeding profile is comparable to that of
warfarin; however, key differences exist. For example, dabigatran is associated with a lower incidence of intracranial
hemorrhage; this may be offset by the increased rate of
gastrointestinal bleeding and concern for ACS. In the first
quarter of 2011, the Institute for Safe Medication Practices
(ISMP) identified 932 serious adverse drug events attributed
to dabigatran.33 Of the 932 adverse drug events identified,
293 were further classified as gastrointestinal hemorrhage.
The ISMP elaborated further by highlighting elderly patients’
predisposition to hemorrhagic complications with dabigatran
therapy. The median age for dabigatran case reports during this quarter was 80 years compared to a median age of
56 years for all other drugs,33 further emphasizing the need
for assessment of individual patient characteristics and preexisting conditions prior to therapy selection.
Another disadvantage is the need for parenteral anticoagulation for 5–10 days before dabigatran initiation.
Rivaroxaban and apixaban have both been studied as an
initial treatment for acute VTE without the need to wait 5 days
prior to starting therapy. This caveat to dabigatran therapy
may dissuade its use in the acute treatment of VTE.

Conclusion
Dabigatran remains an alternative to warfarin for the treatment of VTE. Selection of this therapy may be appropriate for
those patients unable to tolerate the requirements of warfarin
management. Patient characteristics, as well as cost, will need
to be considered on a case-by-case basis. The therapeutic
armament for the treatment of VTE has increased considerably over the last 5 years. Despite the available options,
clinicians must ensure that the drug characteristics align with
patient characteristics to optimize patient outcomes.
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References

1. Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factors for deep vein
thrombosis in inpatients aged 65 and older: a case-control multicenter
study. J Am Geriatr Soc. 2004;52(8):1299–1304.
2. Bramlage P, Pittrow D, Kirch W. Current concepts for the prevention of
venous thromboembolism. Eur J Clin Invest. 2005;35 Suppl 1:4–11.

Journal of Blood Medicine 2015:6

Dovepress
3. Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous
thromboembolism in the elderly: efficacy and safety of non-VKA oral
anticoagulants. Thromb J. 2014;12:21.
4. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk
factors for venous thromboembolism. Arterioscler Thromb Vasc Biol.
2012;32(3):563–568.
5. Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment
Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe.
The number of VTE events and associated morbidity and mortality.
Thromb Haemost. 2007;98(4):756–764.
6. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of
clinical venous thromboembolism in the USA: current trends and future
projections. Am J Hematol. 2011;86(2):217–220.
7. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood.
2007;109(2):422–430.
8. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones
and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22(2):201–210.
9. Gould MK, Garcia DA, Wren SM, et al; American College of Chest
Physicians. Prevention of VTE in nonorthopedic surgical patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl):e227S–e277S.
10. Kahn SR, Lim W, Dunn AS, et al; American College of Chest
Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
2012;141(2 Suppl):e195S–e226S.
11. Falck-Ytter Y, Francis CW, Johanson NA, et al; American College of
Chest Physicians. Prevention of VTE in orthopedic surgery patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl):e278S–e325S.
12. Kearon C. Natural history of venous thromboembolism. Circulation.
2003;107(23 Suppl 1):I22–I30.
13. Bates SM, Jaeschke R, Stevens SM, et al; American College of
Chest Physicians. Diagnosis of DVT: Antithrombotic Therapy
and Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;
141(2 Suppl):e351S–e418S.
14. Gorman WP, Davis KR, Donnelly R. ABC of arterial and venous
disease. Swollen lower limb-1: general assessment and deep vein
thrombosis. BMJ. 2000;320(7247):1453–1456.
15. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest
Physicians. Antithrombotic therapy for VTE disease: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
2012;141(2 Suppl):e419S–e494S.
16. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10):
1037–1052.
17. Mos IC, Klok FA, Kroft LJ, de Roos A, Huisman MV. Imaging tests
in the diagnosis of pulmonary embolism. Semin Respir Crit Care Med.
2012;33(2):138–143.
18. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein
thrombosis. Lancet. 2012;379(9828):1835–1846.
19. Dobesh PP, Fanikos J. New oral anticoagulants for the treatment of
venous thromboembolism: understanding differences and similarities.
Drugs. 2014;74(17):2015–2032.
20. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a
new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin
Pharmacol. 2007;64(3):292–303.

Journal of Blood Medicine 2015:6

Dabigatran, DVT, and pulmonary embolism
21. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin
Pharmacokinet. 2010;49(4):259–268.
22. Pradaxa® (dabigatran etexilate mesylate) capsules [package insert].
Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2015.
23. Mo Y, Yam FK. Recent advances in the development of specific
antidotes for target-specific oral anticoagulants. Pharmacotherapy.
2015;35(2):198–207.
24. Boehringer Ingelheim. Reversal of dabigatran anticoagulant effect
with idarucizumab. Available from: https://clinicaltrials.gov/ct2/show/
NCT02104947. NLM identifier: NCT02104947. Accessed March 23,
2015.
25. Boehringer Ingelheim. Boehringer Ingelheim submits applications
for approval of idarucizumab*, specific reversal agent to dabigatran
etexilate (Pradaxa®), to EMA, FDA and Health Canada [press release].
Ingelheim, Germany: Boehringer Ingelheim; 2015 [March 3]. Available
from: https://www.boehringer-ingelheim.com/news/news_releases/
press_releases/2015/03_march_2015_dabigatranetexilate.html.
Accessed March 23, 2015.
26. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study
Group. Dabigatran versus warfarin in the treatment of acute venous
thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
27. Schulman S, Kakkar AK, Goldhaber SZ, et al; RE-COVER II Trial
Investigators. Treatment of acute venous thromboembolism with dabigatran
or warfarin and pooled analysis. Circulation. 2014;129(7):764–772.
28. Ogbonna KC, Jeffery SM. Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial
fibrillation in the elderly. Drugs Aging. 2013;30(7):513–525.
29. Schulman S, Kearon C, Kakkar AK, et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran,
warfarin, or placebo in venous thromboembolism. N Engl J Med.
2013;368(8):709–718.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee
and Investigators. N Engl J Med. 2009;361(12):1139–1151.
31. Laporte S, Mismetti P, Décousus H, et al; RIETE Investigators. Clinical
predictors for fatal pulmonary embolism in 15,520 patients with venous
thromboembolism: findings from the Registro Informatizado de la
Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation.
2008;117(13):1711–1716.
32. Lyman GH, Khorana AA, Kuderer NM, et al; American Society
of Clinical Oncology Clinical Practice. Venous thromboembolism
prophylaxis and treatment in patients with cancer: American Society
of Clinical Oncology clinical practice guideline update. J Clin Oncol.
2013;31(17):2189–2204.
33. Institute for Safe Medication Practices. QuarterWatch. Monitoring
FDA MedWatch Reports: Signals for Dabigatran and Metoclopramide.
Horsham, PA: Institute for Safe Medication Practices; 2012. Available
from: http://www.ismp.org/QuarterWatch/pdfs/2011Q1.pdf. Accessed
April 20, 2015.
34. Frederick AA Jr, Spencer FA. Risk factors for venous thromboembolism.
Circulation. 2003;107(23 Suppl I):9–16.
35. Fenner KS, Troutman MD, Kempshall S et al. Drug-drug interactions
mediated through P-glycoprotein: clinical relevance and in vitro-in
vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther.
2009;85(2):173–181.

submit your manuscript | www.dovepress.com

Dovepress

183

Ogbonna and Dixon

Journal of Blood Medicine

Publish your work in this journal
The Journal of Blood Medicine is an international, peer-reviewed, open
access, online journal publishing laboratory, experimental and clinical aspects
of all topics pertaining to blood based medicine including but not limited to:
Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,
and Blood banking logistics; Immunohematology; Artificial and alternative

Dovepress

Dovepress
blood based therapeutics; Hematology; Biotechnology/nanotechnology of
blood related medicine; Legal aspects of blood medicine; Historical perspectives. The manuscript management system is completely online and includes
a very quick and fair peer-review system. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/Journal-of-blood-medicine-journal

184

submit your manuscript | www.dovepress.com

Dovepress

Journal of Blood Medicine 2015:6

